You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Hologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own.
Hologic said that Biotheranostics' PCR-based gene expression tests have been validated in large studies in areas of oncology with high growth potential.
The skin cancer diagnostics company said it delivered 7 percent more DecisionDx-Melanoma test results in Q3 2020 than in the previous year's third quarter.
The test is designed to measure the expression of IFI27, a gene strongly correlated with disease progression in influenza and COVID-19.
The funding is part of a BARDA contract worth up to $72 million to support the development of a test to diagnose acute infection at the point of care.
Inflammatix said that if its test obtains Emergency Use Authorization next year, clinicians will be able to better gauge the severity of a COVID-19 patient's infection.
CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.
The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.
The company recently said it was discontinuing development of its original and only in-house developed assay after a failed clinical validation.